Viemed Healthcare (VMD) Projected to Announce Earnings on Monday

Posted by Francis Steltz on Jul 27th, 2026

Viemed Healthcare (NASDAQ:VMD – Get Free Report) is projected to announce its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to post earnings of $0.10 per share and revenue of $78.00 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 11:00 AM ET.

Viemed Healthcare (NASDAQ:VMD – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). Viemed Healthcare had a net margin of 5.20% and a return on equity of 10.52%. The company had revenue of $75.41 million during the quarter, compared to analyst estimates of $74.40 million. On average, analysts expect Viemed Healthcare to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Viemed Healthcare Price Performance

NASDAQ:VMD opened at $11.77 on Monday. The stock has a market capitalization of $451.26 million, a PE ratio of 31.81 and a beta of 1.10. Viemed Healthcare has a 1-year low of $5.93 and a 1-year high of $12.61. The firm has a fifty day simple moving average of $10.90 and a 200 day simple moving average of $9.50. The company has a current ratio of 1.22, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c+)” rating on shares of Viemed Healthcare in a research note on Friday, July 17th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Viemed Healthcare has an average rating of “Hold”.

Check Out Our Latest Stock Analysis on Viemed Healthcare

Insider Transactions at Viemed Healthcare

In other Viemed Healthcare news, insider William Frazier sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $11.72, for a total value of $117,200.00. Following the completion of the sale, the insider owned 73,214 shares of the company’s stock, valued at $858,068.08. The trade was a 12.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Timothy Smokoff sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $11.50, for a total transaction of $230,000.00. Following the transaction, the director owned 75,518 shares in the company, valued at approximately $868,457. The trade was a 20.94% decrease in their position. The disclosure for this sale is available in the SEC filing. 20.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Viemed Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. bought a new stake in shares of Viemed Healthcare in the fourth quarter valued at approximately $46,000. Quarry LP bought a new position in Viemed Healthcare during the 3rd quarter worth $48,000. AQR Capital Management LLC bought a new position in Viemed Healthcare during the 1st quarter worth $90,000. Invesco Ltd. increased its stake in Viemed Healthcare by 25.5% during the 2nd quarter. Invesco Ltd. now owns 18,652 shares of the company’s stock worth $129,000 after acquiring an additional 3,795 shares during the period. Finally, MetLife Investment Management LLC raised its holdings in Viemed Healthcare by 52.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,565 shares of the company’s stock valued at $138,000 after acquiring an additional 6,408 shares in the last quarter. 74.24% of the stock is currently owned by institutional investors and hedge funds.

About Viemed Healthcare

(Get Free Report)

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.